DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/4lmbxx/global_drugs_retai) has announced the addition of the "Global Drugs Retail Industry 2012-2017: Trends, Profits and Forecast Analysis" report to their offering. The growing aging population and increasing health consciousness among the global populace is likely to drive the global retail drug industry. The drug industry consists of pharmacies and drug stores engaged in retailing prescription or nonprescription drugs and medicines, cosmetics, beauty supplies, perfume, optical goods, and health and personal care stores. The industry is highly fragmented and dependent upon macroeconomic factors such as GDP, disposable income, and consumer spending. APAC depicts the best growth prospects for retailers in forth coming years with increasing aging population, health consciousness, and consumer demand. Increasing industry share of Asian economies in world trade and rapid industrialization in emerging economies are expected to boost demand in this region. Thus, APAC is expected to grow at a faster pace than other regions. This study provides an overview of the global retail drug industry. The report tracks market sizing for four geographic regions of the global retail drug industry. To make any investment or strategic decision, you need adequate and timely information. This market report fulfills this core need. Some of … Continue reading →

Enlarge Ramon Espinosa/AP Generic antiretroviral drugs have made treatment widely available for people like Marie Lourdes Pierre (left), a patient with HIV/AIDS in Haiti. Generic antiretroviral drugs have made treatment widely available for people like Marie Lourdes Pierre (left), a patient with HIV/AIDS in Haiti. In the absence of a cure or vaccine for HIV/AIDS, drug treatment has at least helped lower the pandemic's toll. Since 2003, much of the treatment dispensed in hard-hit countries has come in the form of generic versions of previously expensive drugs. The President's Emergency Plan For AIDS Relief, or PEPFAR, has paid for quite a bit of the medicine. While PEPFAR is credited with having saved 1.2 million lives, authors of a study published in the latest Health Affairs say its success was made possible, in no small part, by changes at the Food and Drug Administration. Starting in 2004, the agency began expediting the tentative approval of generic drugs, allowing production of more than 140 generic versions of common antiretrovirals, or ARVs, to be offered through PEPFAR, according to the study. A tentative FDA approval means the drug meets the agency's standards for safety, effectiveness and manufacturing quality. The approvals are tentative only … Continue reading →